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The effects of metoprolol treatment in patients surviving
acute myocardial infarction have been investigated in a
double-blind randomized study. The patients were strat-
ifiedaccording to age, infarct sizeand type of ventricular
arrhythmias before administration of metoprolol, 100
mg twice daily (n = 154), or placebo (n = 147). All
patients were followed up for 36 months. There were 31
(29 cardiac) and 25 (20 cardiac) deaths in the placebo
and metoprolol groups, respectively. Subgroup analyses
showed a significant reduction of cardiac death in pa-
tients with a large infarct (32.1% with placebo versus
12.5% with metoprolol, p < 0.05) as a result of active
treatment.
Sudden death rates were 14.7% in the placebo versus
5.8% in the metoprolol group (p < 0.05). The incidence
The possibility of a beneficial effect of beta-adrenergic
blockade on mortality after acute myocardial infarction was
proposed by Snow (1) in 1965. This idea received support
from three different studies in the 1970s (2-4), all of which
reported a reduction of sudden deaths. Although there were
also studies that failed to show any influence on mortality,
as later reviewed by Hampton (5) and Breckenridge (6), we
were sufficiently impressed by the positive studies to per-
form this investigation in an attempt to obtain some infor-
mation on the modes of action for a probable beneficial
effect. Our primary aim was to study the effect of metoprolol
on chronic ventricular arrhythmias, exercise performance
and standard biochemical values and to follow up the mor-
bidity and mortality in different risk strata. Although those
latter end points were not the primary aim of the study, we
believe that the results in these respects are worth presen-
tation in a special report.
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of nonfatal reinfarction was 21.1% in the placebo versus
11.7% in the metoprolol group (p < 0.05). The reduction
in nonfatal reinfarction was similar in all pretreatment
risk strata. The difference between the two groups in
cumulative number of cardiac deaths and patients ex-
periencing nonfatal reinfarction increased throughout
the study. Furthermore, cerebrovascular events (p <
0.05) and coronary bypass surgery (p = 0.058) were
more frequent in the placebo group.
In conclusion, after 36 months of metoprolol treat-
ment after myocardial infarction , there was a significant
reduction of nonfatal reinfarction and sudden death in
all patients and a reduction of cardiac death in those
with a large infarct.
(J Am Coli CardioI1985;5:1428-37)
Our study is characterized by prospective patient strati-
fication according to the three main factors previously shown
to carry prognostic information after a myocardial infarction
at our institution (7,8). The patients were thereafter ran-
domly allocated to double-blind treatment with metoprolol
or placebo. While our study was under progress, two large,
well designed, long-term postinfarction trials of beta-ad-
renergic blocking agents (9,10) showed that total mortality
after myocardial infarction can be reduced by treatment with
some of these agents. Furthermore , early intervention with
metoprolol in patients with acute myocardial infarction has
been shown to reduce mortality during a 3 month treatment
period (II ). However, a number of questions, including the
clarification of mode of action, patient selection for treat-
ment as well as optimal duration of treatment, remain un-
answered by these studies.
Methods
Patient recruitment. Patient inclusion started in May
1976 and continued until December 1980. The study was
started at the Serafimer Hospital in Stockholm (124,000
inhabitant catchment area). Owing to the closing of this
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Table 1. Reasons for Exclusion of Patients From Participation
in Study
n
Bundle branch block 23
Atrial fibrillation 16
Atrioventricular block 7
Heart failure I7
Hypotension 7
Obstructive pulmonary disease 3
Severe intermittent claudication 2
Need for beta-adrenergic blockade therapy 44
Other major disease is
Unwillingness to participate 23
Total 157
hospital, the study was continued at the suburban Danderyd
Hospital (240,000 inhibitant catchment area) . Consecutive
patients with the following criteria were included . 1) Youn-
ger than 70 years of age and residence within catchment
area . 2) Admission to the coronary care unit within 48 hours
from onset of symptoms and development of an acute myo-
cardial infarction. The diagnosis was made on the basis of
two of the following criteria: typical history, development
of Q waves on a standard electrocardiogram and typical
changes in serum enzymes (aspartate aminotransferase, alanine
aminotransferase, creatine kinase and lactate dehydrogen-
ase). 3) Sinus rhythm without complete bundle branch block.
4) Absence of the following : systolic blood pressure less
than 100 mm Hg; severe cardiac failure not responding to
conventional treatment with digitalis and diuretic drugs; se-
vere intermittent claudication; obstructive pulmonary dis-
ease; need for beta-adrenoceptor blockade (that is, severe
angina pectoris or symptomatic arrhythmias responding to
beta-adrenergic blockade); other major disease and unwill-
ingness to participate.
During the inclusion period, 556 patients younger than
70 years of age with acute myocardial infarction were ad-
mitted; 61 patients died in the coronary care unit , 37 were
nonresidents and 157 did not meet the inclusion criteria
Table 2. Stratification Data of the Patients
(Table 1). The remaining 301 patients constituted the study
group , representing 66% of all patients youpger than 70
years of age . All patient s gave their informed consent to
participate in the study, which was approved by the Ethical
Committee at the Serafirner Hospital in Stockholm.
Stratification and randomization. The patients were
stratified according to type of ventricular arrhythmias , age
and estimated infarct size (Table 2). The ventricular ar-
rhythmias were detected by a 6 hour electrocardiographic
recording using telemetry written on paper (2:00 to 5:00 AM
and 9:30 to 12:30 PM) (12), performed 4 days before dis-
charge (1 to 2 weeks after the acute event). The arrhythmias
were graded in six groups: no premature ventricular com-
plexes, uniform, multiform, paired , R on T premature ven-
tricular complexes and ventricular tachycardia. Patients with
paired, R on T premature ventricular complexes and ven-
tricular tachycardia on the initial arrhythmia recording were
not further classified by age because of the assumed small
number of patients in these arrhythmia groups . In the anal-
yses, multiform , paired, R on T premature ventricular com-
plexes and ventricular tachycardia (runs of 2::: three pre-
mature ventricular complexes with a rate of 2::: 100beats/min)
have been denoted as complex ventricular ectopic activity.
The study group was divided into two subsets: patients
65 years of age or older and those younger than 6, years
of age. The peak value of heat-stable lactate dehydrogenase
was used for estimation of infarct size (13). The patients
were classified as having a large infarct (that is, 2:::20 JLkatlliter)
or a small infarct «20 JLkatlliter) . Samples were taken
every 12 hours during the first days and analyzed according
to the method recommended by the Scandinavian Commit-
tee on Enzymes (14). The thermostable fraction of lactate
dehydrogenase represents the isoenzymes I and II and was
determined after inactivation of the heat-labile isoenzymes
of lactate dehydrogenase (15) . The unit katal is the Inter-
national System of Units (Sl) unit of enzymatic activity and
is defined as the catalytic activity of an enzyme which ca-
talyses a reaction rate of I mol/s. One p,katlliter corresponds
to 52 .2 iu .
After stratification , the patients were randomized to dou-
Type of arrhythmia 0 Uni Multi Paired Rff VT
Age (yr) < 65 ~65 < 65 ~65 < 65 ~65 16 to 70 16 to 70 16 to 70
Size of infarct
LOt < 20 23/22 7/8 20/20 10/10 14114 5/8 7/8 1/4 4/4
p.katlliter
LO, ~ 20 15/14 6/5 14/12 5/4 6/9 3/3 615 0/1 1/3
p.katlliter
The ratios represent the number of patients treated with placebo or metoprolol, respectively (placebo/metoprolol), in each stratification group . The
patients were primarily stratified according to type of ventricular arrhythmia registered on a 6 hour electrocardiographic recording, thereafter according
to age and finally according to peak level of LDt (thermostable fraction of lactate dehydrogenase) as an estimate of infarct size . /A-katlliter = microkatals/liter;
o = no premature ventricular complexes (PVCs); Uni, multi, paired and Rff = uniform. multiform, paired and R on T premature ventricular complexes.
respectively; VT = ventricular tachycardia.
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ble-blind treatment with metoprolol, 100 mg, or placebo
given as half a tablet three times daily for 3 days and then
1 tablet twice daily. All tablets were identical in shape, size
and color.
Follow-up study procedures. The patients were fol-
lowed up in the outpatient clinic at 1 and 3 months after
the infarction, and thereafter at 3 month intervals for 36
months. All patients were followed up for 3 years irre-
spective of treatment changes. Blood and urinary chemical
values were analyzed at 1, 3 and 6 months, and thereafter
every 6 months. From these samples compliance was eval-
uated by examining metoprolol content in blood at 6, 12
and 36 months and in urine at 1, 3, 18, 24 and 30 months
follow-up. An electrocardiogram was recorded at rest at the
1, 3, 6, 12, 24 and 36 months visits. After the 36 month
treatment period, the study medication was withdrawn ac-
cording to a specific protocol and withdrawal phenomena
were studied as reported elsewhere (16).
If adverse symptoms developed, suspected to be related
to treatment, the dose was initially halved. If they persisted,
treatment was withdrawn without breaking the study code.
Patients with angina pectoris were primarily treated with
nonbeta-adrenergic blocking antianginal agents. If this was
insufficient, the patients were withdrawn blindly and given
active beta-adrenoceptor blockade. Patients were referred
to coronary artery bypass surgery if unresponsive to optimal
medical treatment including beta-adrenergic blocking agent
therapy. Patients who experienced a nonfatal reinfarction
remained on study treatment unless refractory heart failure,
hypotension or atrioventricular block developed.
End point evaluation. In the evaluation of mortality,
relatives and witnesses of sudden deaths were interviewed
and death certificates and hospital files reviewed. Sudden
death was defined as death occurring without preceding
symptoms or within 2 hours from onset of cardiac symp-
toms. All end point evaluation as well as the determination
Table 3. Characteristics of Patients in Study Group
Placebo p Metoprolol
Variables (n = 147) Value (n = 154)
Age (yr) 59.2 ± 7.2 NS 60.1 ± 6.7
Men (%) 83 NS 78
Smokers (%) 60.3 NS 53.2
Ex-smokers (%) 17.8 NS 18.8
Previous infarction (%) 19.7 NS 20.8
Hypertension before MI (%) 26.5 NS 24.5
Diabetes mellitus before MI (%) 6.1 NS 9.7
Cerebrovascular incidence before MI (%) 2.7 NS 5.2
LOt - max JAokatlliter 19.6 ± 13.7 NS 19.8 ± 14.0
Nontransmural infarction (%) 27.8 NS 25.3
Site of infarction (%)
Anterior 51 NS 44
Inferior 31 NS 38
Unknown 18 NS 18
VF in the CCU (%) 2.7 NS 3.2
VT in the CCU (%) 45.9 NS 36.4
AV-I in the CCU (%) 8.2 NS 11.7
AV-II in the CCU (%) 4.1 NS 3.9
AV-III in the CCU (%) 2.1 NS
LAH in the CCU (%) 13.0 NS 14.9
LBBB in the CCU (%) 1.4 NS 1.9
RBBB in the CCU (%) 2.1 NS I.3
Rales at auscultation in the CCU (%) 66.7 NS 64.7
Maximal respiratory rate in the CCU (per min) 24.2 ± 4.3 NS 23.5 ± 4.3
Heart size (ml/rrr') 470 ± 88 NS 471 ± 89
BP < 90 mm Hg in the CCU (%) 9.8 NS 9.9
Complex PVCs at randomization (%) 33 NS 38
Treatment at discharge (%)
Digitalis 24.0 NS 23.4
Diuretic drugs 47.9 NS 41.6
Antiarrhythmic agents 6.2 NS 5.8
AV-I, -II, -III = first, second and third degree atrioventricular block, respectively; BP = blood pressure;
CCU = coronary care unit; LAH = left anterior hemiblock; LBBB = left bundle branch block; LD, =
thermostable fraction of lactate dehydrogenase; MI = myocardial infarction; PVCs = premature ventricular
complexes; RBBB = right bundle branch block; VF = ventricularfibrillation; VT = ventriculartachycardia.
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Table 4. Withdrawals From Therapy and Dose Reductions During the Follow-up Period
Withdrawals Dose Reductions
Attributed Cause P M P M
Uncontrolled angina 16* 6
Heart failure 1* 7 I I
Symptomatic bradycardia I I 3t 18
Symptomatic arrhythmia 4 2 I I
Hypotension 2
Intermittent claudication 1 5 3 4
Asthma I 2 I I
Nightmares I 2 1
Suspected allergic reactions 3 2
Impotence 2 2 2
Fatigue I 2 4
Gastrointestinal symptoms 2 I
Paresthesias I
Unwillingness to participate 6 6
Total 35 38 15 34
*p < 0.05, t p < 0.01. M '" metoprolol, P '" placebo.
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of sudden death was conducted without knowledge of the
treatment group.
Nonfatal reinfarction was diagnosed if patients were hos-
pitalized and developed a new myocardial infarction or if
new diagno stic Q waves were found on a standard electro-
cardiogram during the follow -up period . Athero sclerot ic
manifestations such as cerebrovascular events and devel -
opment of gangrene requirin g amputation were recorded ,
as was the performance of coronary bypass surgery .
Patients who failed to attend the outpatient clinic were
contacted by telephone and followed up by hospital and
community records to obtain necessary morbidity and mor-
tality data. No patient had missing mortality or morbidity
data during the 36 month follow-up period. Survival of
nonrandomized patients younger than 70 years of age living
within the catchment area was traced by community records.
Statistical analyses. The two groups were compared ac-
cording to the initial treatment allocation , that is, on an
"intention to treat " basis. In the statistical analysis, the chi-
square test and Student's t test were used in the comparisons
of baseline data at entry in the study . Mortalit y and mor-
bidity during the 36 month follow-up period were compared
using the two-tailed chi-square test. A probab ility value of
less than 0.05 was regarded as indicative of a significant
difference ; values were expressed as mean ± standard
deviation .
Results
Comparability of treatment groups and compliance.
Clinical characteristics and stratification data of the ran-
domized patients are shown in Tables 2 and 3. No statis-
tically significant differences were observed between the
two groups in the pretreatment variables considered.
Throughout the follow-up study the heart rates at test were
9.1 ± 2.0 beats/min lower in the metoprolol group. Plasma
and urinary samples were analyzed in 85.8% of scheduled
samples in the metoprolol group. Metoprolol was detected
in 96.7% of these samples .
Side effects. Fifty-one patient s (27 receiving metopro-
101) were withdrawn during the first year . Twenty-two pa-
tients were withdrawn during the second and third years
(six and five , respect ively, receiving metoprolol). With-
drawal due to uncontrolled angina pectoris was significantly
more common in the placebo group and withdrawal due to
heart failure was more common in the metoprolol group (p
< 0 .05) . The dose was reduced in 10 and 25% of the placebo
and metoprolol group, respectively. The reasons for with-
drawal or dose reductions are shown in Table 4.
Figure 1. Cumulative cardiac mortality of patients treated with
metoprolol (M) or placebo (P) during the 36 month follow-up
period after myocardial infarction.
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Table 5. Number of Deaths During the Follow-up, Period
Total Deaths Cardiac Deaths
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<65 years
;;:,65 years
Noncomplex PYCs
Complex Pv'Cs
Small infarct
Large infarct
Patients receiving drug
Patients withdrawn from treatment
Total
Placebo
(n '" 147 [%])
19(17.6)
12(30.8)
19(19.2)
12(25.0)
11(12.1)
20(35.7)
24(21.4)
7(20.0)
31(21.1)
Metoprolol
(n = 154 [%])
14(13.2)
jl(22.9)
15(15.6)
10(17.2)
17(17.3)
8t(l4.3t)
18(15.4)
7(18.4)
25(16.2)
Placebo
(n = 147 [%])
17(15.7)
12(30.8)
18(18.2)
11(22.9)
11(12.1)
18(32.1)
22(19.6)
7(20.0)
29(19.7)
Metopralol
(n = 154 [%])
13(12.3)
7(14.6)
11(11.5)
9(15.5)
13(13.3)
7*(12.5*)
15(12.8)
5(13.2)
20(13,0)
*p < 0.05; tp < 0.01. Abbreviations as in Table 3.
Major Events
Deaths. According to "intention to treat" the number
of deaths was 31 (2l.1 %) in the placebo group and 25
(16.2%) in the metoprolol group (p = NS). Corresponding
statisticsfor cardiac mortality were 29 (19.7%) and 20 (13.0%)
(p = NS) (Fig. 1). The noncardiac deaths in the placebo
group were due to neoplasms. In the metoprolol group there
were two deaths due to neoplasms and one death each due
to purulent meningitis, pulmonary embolism and compli-
cations of noncardiac surgery. Total and cardiac deaths ac-
cording to the pretreatment stratification are shown in
Table 5.
In patients with a large infarct (that is, thermostable
fraction of lactate dehydrogenase ~20 jLkatiliter) (Fig. 2),
a significant reduction in cardiac mortality was found in
the metoprolol group (p < 0.05). Cumulative cardiac mor-
tality in the different age groups is shown in Figure 3. There
were 52% fewer deaths in the metoprolol group as compared
with the placebo group among patients 65 to 69 years of
age (p = 0.068). The reduction in cardiac mortality was
similar to patients with or without pretreatment complex
ventricular ectopic activity (32.3 and 36.8%, respectively)
(Fig. 4). However, in patients without such ectopic activity,
mortality during the initial 18 months was almost identical
in the two treatment groups, that is, the mortality curves
showed a divergence only during the later part of the follow-
up study. In contrast, the reduction in mortality among
patients with complex ventricular ectopic activity was seen
mainly during tile first 2 years (18.8% in the placebo versus
6.9% in the metoprolol group). After 24 months the mor-
tality curves for these patients subgroups were parallel. The
cumulative numbers of cardiac deaths seemed to diverge
throughout the follow-up period (Fig. I to 5). The 3 year
mortality among the eligible but nonrandomized patients
was 31.5% (n = 39).
There wrre 21 suddden deaths in the placebo group com-
pared with 9 in the metoprolol group (p < 0.05) (Fig. 5).
This reduction was most evident in patients with a large
infarct, that is, 13 versus I sudden death, respectively (p
< 0.(01).
No~f~tal remfaretiens. Figure 6 shows the cumulative
proportion of patients who had a nonfatal reinfarction. There
were significantly fewer such patients in the metoprolol
group (n = 18,11.7%) than in the control group (n = 31,
21.1 %) (p < 0.05). In the metoprolol group three patients
Figure 2. Cumulative cardiac mor-
tality according to pretreatment infarct
size. Small infarcts = thermostable
fraction of lactate dehydrogenase less
than 20 /Lkatlliter; large infarcts =
thermostable fraction of lactate de-
hydrogenase 20 or more J+katlliter. The
difference between patients with a large
infarct treated with placebo (P) or me-
toprolol (~) is significant (p < 0.05).
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Figure 3. Cumulative cardiac mor-
tality according to pretreatment age
(2:65 or < 65 years of age). M = me-
toprolol , P = placebo .
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experienced more than one nonfatal reinfarction versus four
patients in the placebo group. The reduction in nonfatal
reinfarctions was similar in all stratification groups (Table
6). In an analysis of major cardiac events (that is, either
cardiac death or nonfatal reinfarction) , there was also a
statistically significant reduction in the metoprolol group
(31 versus 49 , p < 0 .01).
Other ischemic manifestations . Coronary artery by-
pass surgery for intractable angina unresponsive to maximal
medical treatment including active beta-adrenergic blockade
was performed in nine placebo - and three metoprolol-treated
patients (p = 0.058) . Cerebrovascular events occurred in
II placebo-treated patients (5 with strokes and 6 with tran-
sient ischemic attacks) and 3 metoprolol -treated patients (I
with stroke and 2 with transient ischemic attacks) (p <
0 .05) . Three additional placebo -treated patients developed
severe peripheral arterial insufficiency requiring lower limb
amputation.
Discussion
Study design. To obtain information on possible modes
of action and indication for metoprolol therapy , prospective
stratification into high and low risk groups according to
electrical instability (8) , age and degree of myocardial dam-
age (7) was performed and combined with repeated long-
term electrocardiographic monitoring and exercise tests dur-
ing the study. The stratification before randomization proved
effective because the two treatment groups were nearly iden-
tical in pretreatment clinical variables and the outcome dif-
fered in low and high risk patients in the control group.
Electrical instabilitywas evaluated by long-term electro-
cardiographic recordings. To avoid too many subgroups
additional noninvasive measures for prognostication, that
is, markers of ischemia, were not used. Preliminary data
concerning the results of long-term electrocardiographic re-
cordings and exercise tests have been published (17 ,18),
and subsequent reports with complete results on these topics
will be published.
The thermostabLe fraction of Lactate dehydrogenase that
was used as an indicatorof infarct size has a relatively high
specificity for myocardial damage, although enzymes from
lysed blood cells also will contribute . The long half-life in
serum of lactate dehydrogenase makes it possible to obtain
accurate near-peak values with blood sampling only twice
Non-complex PVCs ComplexPVCs
Figure 4. Cumulative cardiac mor-
tality according to pretreatment ven-
tricular arrhythmias (noncomplex and
complex premature ventricular com-
plexes (PYes)). M = metoprolol, P
= placebo.
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Non-fatal reinfarctions
(19). With more frequent sampling, creatine kinase might
have provided better estimates of the infarct size (20).
Side effects. In the design of our study, the dose of
metoprolol was 100 mg twice daily. This rather high dose
was chosen to obtain effective beta-adrenoreceptor blockade
in every treated patient. This is probably one explanation
for the high cumulative number of patients requiring dose
reduction or withdrawal of treatment. As could be expected,
more patients in the placebo group were withdrawn because
of uncontrolled angina pectoris and more patients in the
metoprolol group because of heart failure. However, the
incidence of refractory heart failure necessitating withdrawal
of metoprolol was low, a finding in agreement with other
beta-adrenergic blocking agent studies (9-11).
Applicability. We included 66% of all patients younger
than 70 years of age who developed myocardial infarction.
Of the 157 excluded patients, 44 were openly treated with
beta-adrenergic blocking agents. Accordingly, approxi-
mately 75% of the patients younger than 70 years of age
were considered for or treated with these agents. These
statistics, in connection with the fact that most patients with
acute myocardial infarction in Sweden are treated in coro-
nary care units, suggest that the majority of this patient
group can be treated with long-term beta-adrenergic block-
ade provided that treatment is started with careful patient
monitoring.
The analyses of metoprolol in blood and urine indicated
a high level of compliance. During the follow-up study no
attempts were made to guess type of treatment in the in-
dividual patient. The double-blind design is applicable also
to beta-adrenergic blocking agent studies and the level of
investigator blindness in the present study may be illus-
trated by the relatively large number of dose reductions
occurring in the placebo group. Furthermore, the moderate
reduction in heart rate and the equal withdrawal rates in the
two groups prevented unblinding of treatment.
Mortality. On the basis of previous, well performed,
large postinfarction studies, it is evident that some beta-
adrenergic blocking agents reduce mortality by approxi-
mately one-third during a treatment period of 2 to 3 years
(9,10). In our study we found a reduction of cardiac mor-
tality of the same magnitude (34%). This reduction in car-
diac mortality did not reach statistical significance, as was
to be expected from our sample size (21). In agreement with
previous studies (2-4,9,10,22), we found a significant re-
duction (59%) in sudden deaths among treated patients.
Therefore, our study supports the hypothesis of a favorable
effect of metoprolol treatment on prognosis after myocardial
infarction, despite the lack of a statistically significant re-
duction of cardiac mortality in the entire study group.
Beneficial effects on mortality are most likely to be de-
tected in high risk patients. Accordingly, cardiac mortality
was more than halved in patients vith a large infarct and
in those older than 64 years of age. In contrast, no major
p< 0.05
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Figure 5. Cumulative incidence of sudden death during the fol-
low-up period.Thedifference between placebo (P) and metoprolol
(M) at 36 months is significant (p < 0.05).
Figure 6. Cumulative incidence of patients with nonfatal rein-
farction during the follow-up period. The difference between pla-
cebo (P) and metoprolol (M) is significant (p < 0.05).
a day and also in patients with long delay. Peak values of
the thermostable fraction of lactate dehydrogenase, obtained
by this sampling technique, were shown in a previous study
from our department to correlate with autopsy findings of
infarct size (13). In that previous study, lactate dehydro-
genase measurements were expressed in International Units
(IV). In the present study, lactate dehydrogenase has been
expressed in jLkat/liter as a result of the general conversion
to SI units for biochemical measurements adopted in Sweden
in 1975. In a recent study, the prognostic usefulness of the
enzymatically estimated infarct size, measured as the ther-
mostable fraction of lactate dehydrogenase, has been shown
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Table 6. Number of Patients Experiencing Nonfatal Reinfarction During the Follow-up Period
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<65 years
~65 years
Noncomplex PVCs
Complex PVCs
Small infarct
Large infarct
Patients on drug
Patients withdrawn from treatment
Total
*p < 0.05. Abbreviations as in Table 3.
Placebo
(n = 147 [%])
21(19.4)
10(25.6)
20(20.2)
11(22.9)
18(19.8)
13(23.2)
27(24.1)
4(11.4)
31(21.1)
Metoprolol
(n = 154 [%])
13(12.3)
5(10.4)
10(10.4)
8(13.8)
11(11.2)
7(12.5)
16(13.7)
2(5.4)
18*(11.7*)
effect on mortality was found among younger patients and
those with a small infarct. Our favorable findings of me-
toprolol treatment in the elderly are in contrast to those of
a Danish study with alprenolol (23). In accordance with our
findings, this adverse effect was not found in other suidies
with early (11) or late intervention (24,25) with beta-ad-
renergic blocking agents.
Ventricular arrhythmias. A similar, although not statis-
tically significant, effect on 3 year mortality was seen both
in patients presenting complex ventricular ectopic activity
and in those without such ectopic activity. Still, the different
configurations of the mortality curves for patients with or
without complex ventricular ectopic activity seem to indi-
cate an initial more favorable effect on outcome in those in
whom such arrhythmia was present before treatment. Our
findings in this respect may partly be explained by the ob-
servations in a previous study showing that the prognostic
significance of complex ventricular ectopic activity after
myocardial infarction is relevant only for the subsequent 12
months. After this period a new classification of ventricular
arrhythmias is necessary to obtain prognostic information
for the following 12 months (26).
Antifibrillatory effect ofmetoprolol. In a previous report
on our patients (19), we found a continuous progression in
number as well as complexity of premature ventricular com-
plexes in the control group during the first year after the
infarction. This progression was blunted by metoprolol. This
finding may indicate some effect other than a classic an-
tiarrhythmic one, because that type of drug would not only
blunt a progression but also continuously reduce arrhyth-
mias. However, in view of the reduction in sudden deaths
an antifibrillatory effect may be involved. This is in agree-
ment with the observed antifibrillatory effect by metoprolol
in acute myocardial infarction (27). Whether this effect is
a primary action due to the beta-adrenergic blockade or an
indirect action due to a reduction of myocardial ischemia
remains to be determined. An antifibrillatory effect may
possibly have contributed to the incongruence between the
results on nonfatal (31 in the placebo versus 18 in the me-
toprolol group) and fatal reinfarctions (7 and 9, respec-
tively); that is, some of the patients in the placebo group
who died suddenly might have survived long enough to
develop reinfarction if they had been treated with metopro-
101. However, this cannot be the only explanation of our
findings, because the incidence of major cardiac events was
significantly greater in the placebo group.
Duration of beneficial effect on mortality. In two pre-
vious postinfarction studies in which significant reductions
in cardiac mortality were found (9,10), the beneficial effects
were seen mainly during the initial 12 to 18 months of
treatment. In contrast, the positive effect on mortality in our
patients was most prominent during the second and third
years. The low number of total deaths during the first year
in our study suggests that this difference in time courses
should be interpreted with caution. Furthermore, our study
group is not large enough to compare the beneficial effect
during different parts of the follow-up period. Another pos-
sible explanation for the different configurations of the cu-
mulative mortality curves may be the different designs in
the Beta-Blocker Heart Attack Trial (10) and in the Nor-
wegian timolol study (9) with marked declines in the number
of patients with time (that is, heterogeneous length of fol-
low-up study).
Morbidity. In one previous study (9), the incidence of
nonfatal reinfarction was significantly reduced (28%) in the
treated patients. We found a similar and significant reduction
(45%) in the number of patients experiencing a recurrent
nonfatal infarction regardless of the pretreatment risk strata
chosen in this study. In one additional long-term study, the
incidence of all recurrent reinfarctions, fatal and nonfatal
taken together, was significantly reduced by active treatment
(28).
Protective effect against myocardial infarction. The
reductions in mortality and nonfatal reinfarction are sugges-
tive of a protective effect on the myocardium by metoprolol.
This may partly be due to a lowered oxygen demand by
effects on heart rate, blood pressure and myocardial con-
tractility. However, in view of the significantly lower in-
cidence of cerebrovascular events and the tendencies to de-
creased need for coronary bypass surgery and lesser incidence
1436 OLSSON ET AL.
METOPROLOL AFTER MYOCARDIAL INFARCTION
JACCVol. 5, No.6
June 1985:1428-37
of severe peripheral arterial insufficiency, it is tempting to
suggest a general protection against ischemic manifesta-
tions. A direct effect on tissues, an effect on tissue perfusion
by improved microcirculation or a reduction in the pro-
gression rate of the atherosclerotic process itself may be
involved in this context. Both latter mechanisms receive
support from studies showing increased myocardial capillary
density after long-term propranolol treatment (29) and in-
hibition of thromboxane Az synthesis and platelet aggre-
gation by metoprolol, propranolol and timolol (30). Beta-
adrenergic blocking agents have also been shown to induce
an increase of serum triglycerides and a decrease in high
density lipoprotein cholesterol (31,32). The effect of these
changes during extreme long-term beta-adrenergic blockade
(> than 3 years) is unknown. Effects on blood pressure by
active treatment may have contributed to the lesser incidence
of cerebrovascular events and severe peripheral arterial in-
sufficiency, although treatment for hypertension was given
if indicated.
Conclusions and clinical importance. In accordance
with previous beta-adrenergic blocking agent trials (9-11),
our results indicate reductions in cardiac death, especially
sudden death, nonfatal reinfarction and other manifestations
of ischemia by long-term postinfarction treatment with me-
toprolol. The reduction in mortality was most prominent in
high risk patients, that is, older patients and those with a
large infarction. Reduction in nonfatal reinfarction was sim-
ilar in all risk strata. The beneficial effect of long-term
metoprolol treatment after myocardial infarction seems to
be continuous during a 3 year period. Long-term adminis-
tration of metoprolol, 100 to 200 mg daily, to postinfarction
patients without contraindications for beta-adrenergic block-
ade appears safe and may be continued for at least 3 years,
probably even longer. Patients at high risk for death seem
to be identifiable and the therapeutic effect is the most pro-
nounced in them. However, patients at high risk for nonfatal
reinfarction seem not to be as readily identified with our
stratification and the therapeutic effect on this variable was
equal in all strata.
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